Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?

Publisher： Bentham Science Publishers

E-ISSN： 2212-4055|10|4|236-246

ISSN： 1871-5281

Source： Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol.10, Iss.4, 2011-01, pp. : 236-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target

By Macphee Colin   Benson G Martin   Shi Yi   Zalewski Andrew  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 671-679

Informa Healthcare

Access to resources Recommend Favorite

Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease

By  

Current Pharmaceutical Design, Vol. 24, Iss. 3, 2018-04 ,pp. : 291-296

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 33, 2011-11 ,pp. : 3656-3661

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

By Macphee Colin H   Suckling Keith E  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 3, 2002-06 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6256-6269

Bentham Science Publishers

Access to resources Recommend Favorite